Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.10
CRL's Cash-to-Debt is ranked lower than
92% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. CRL: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
CRL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.3 Max: 15.68
Current: 0.1
0.04
15.68
Equity-to-Asset 0.31
CRL's Equity-to-Asset is ranked lower than
83% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. CRL: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
CRL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.51 Max: 0.72
Current: 0.31
-0.3
0.72
Interest Coverage 8.57
CRL's Interest Coverage is ranked lower than
72% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. CRL: 8.57 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.2 Max: 14.87
Current: 8.57
4.09
14.87
Piotroski F-Score: 4
Altman Z-Score: 2.48
Beneish M-Score: -2.48
WACC vs ROIC
6.79%
9.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.12
CRL's Operating Margin % is ranked higher than
80% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. CRL: 14.12 )
Ranked among companies with meaningful Operating Margin % only.
CRL' s Operating Margin % Range Over the Past 10 Years
Min: -33.48  Med: 14.3 Max: 18.46
Current: 14.12
-33.48
18.46
Net Margin % 9.20
CRL's Net Margin % is ranked higher than
78% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. CRL: 9.20 )
Ranked among companies with meaningful Net Margin % only.
CRL' s Net Margin % Range Over the Past 10 Years
Min: -38.84  Med: 9.4 Max: 12.55
Current: 9.2
-38.84
12.55
ROE % 19.11
CRL's ROE % is ranked higher than
85% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. CRL: 19.11 )
Ranked among companies with meaningful ROE % only.
CRL' s ROE % Range Over the Past 10 Years
Min: -34.11  Med: 16.92 Max: 21.25
Current: 19.11
-34.11
21.25
ROA % 6.27
CRL's ROA % is ranked higher than
72% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. CRL: 6.27 )
Ranked among companies with meaningful ROA % only.
CRL' s ROA % Range Over the Past 10 Years
Min: -21.02  Med: 6.29 Max: 7.58
Current: 6.27
-21.02
7.58
ROC (Joel Greenblatt) % 28.62
CRL's ROC (Joel Greenblatt) % is ranked higher than
70% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. CRL: 28.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 32.31
Current: 28.62
-50.32
32.31
3-Year Revenue Growth Rate 13.40
CRL's 3-Year Revenue Growth Rate is ranked higher than
76% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. CRL: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 13.4
-17.6
13.4
3-Year EBITDA Growth Rate 14.20
CRL's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. CRL: 14.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.2  Med: 8.15 Max: 25.2
Current: 14.2
-18.2
25.2
3-Year EPS without NRI Growth Rate 14.40
CRL's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. CRL: 14.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 9.35 Max: 43.3
Current: 14.4
-29.4
43.3
GuruFocus has detected 3 Warning Signs with Charles River Laboratories International Inc $CRL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CRL Guru Trades in Q2 2016

Robert Olstein 55,901 sh (+130.18%)
David Dreman Sold Out
Steven Cohen Sold Out
Ken Fisher 516,128 sh (-2.59%)
Westport Asset Management 150,000 sh (-3.23%)
Pioneer Investments 271,726 sh (-7.42%)
John Rogers 1,464,130 sh (-12.17%)
Jim Simons 780,109 sh (-17.90%)
PRIMECAP Management 970,660 sh (-19.99%)
Paul Tudor Jones 162,837 sh (-38.45%)
Joel Greenblatt 11,856 sh (-83.12%)
» More
Q3 2016

CRL Guru Trades in Q3 2016

Robert Olstein 85,625 sh (+53.17%)
Jim Simons 935,909 sh (+19.97%)
Pioneer Investments 297,709 sh (+9.56%)
Joel Greenblatt Sold Out
Ken Fisher 508,660 sh (-1.45%)
John Rogers 1,426,842 sh (-2.55%)
PRIMECAP Management 909,660 sh (-6.28%)
Paul Tudor Jones 8,900 sh (-94.53%)
» More
Q4 2016

CRL Guru Trades in Q4 2016

Joel Greenblatt 2,750 sh (New)
Robert Olstein 136,035 sh (+58.87%)
Jim Simons 1,120,209 sh (+19.69%)
John Rogers 1,576,856 sh (+10.51%)
Ken Fisher 490,104 sh (-3.65%)
PRIMECAP Management 875,000 sh (-3.81%)
Paul Tudor Jones 8,520 sh (-4.27%)
Pioneer Investments 164,423 sh (-44.77%)
» More
Q1 2017

CRL Guru Trades in Q1 2017

Ken Fisher 463,712 sh (-5.38%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8732
Compare:NAS:ICLR, NAS:PRAH, OTCPK:SWTUY, NAS:CPHD, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, OTCPK:DSRLF, NAS:PRXL, NAS:EXAS, NYSE:BIO.B, NAS:NEOG, NAS:INCR, NYSE:PKI, NAS:QGEN, NAS:MYGN, NAS:DXCM, NAS:AXDX, NAS:VREX » details
Traded in other countries:RV6.Germany,
Headquarter Location:USA
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and its manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl - Jan 20, 2017

Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River.



From John Rogers (Trades, Portfolio)' Ariel Fund fourth quarter 2016 commentary.



Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Guru stock highlight
Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River. Read more...
Carl Data Solutions Announces Closing of Initial Tranche of $2,000,000 Growth Financing Agreement With AIP Asset Management

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 30, 2016) - Further to its press release dated April 25, 2016, Carl Data Solutions Inc. (CSE:CRL)(FRANKFURT:7C5) ("Carl" or the "Company"), a developer of Big-Data-as-a-Service ("BDaaS") and Internet-of-Things ("IoT") solutions for data collection and analysis, is pleased to announce that it has executed a Note Purchase Agreement (the "Agreement") with AIP Asset Management Inc. ("AIP") pursuant to which Carl has agreed to issue certain funds of AIP (collectively, the "Holders") senior secured collateralized convertible notes (the "Notes") in the aggregate principal amount of CAD $2,000,000 (the "Offering"). The Company has received in escrow gross proceeds of $2,000,000. In connection with the closing of the first tranche of the Offering, the Company has issued Notes in the aggregate principal amount of $500,000 (the "Initial Notes"). Notes representing the balance of the $2,000,000 (the "Additional Notes") will be issued upon satisfaction of the various closing conditions as set out in the Agreement. The Notes are due and payable two years from their respective date of issue, and will bear an interest rate of 10% per annum calculated and payable monthly, in advance. At the option of the Holders, the Notes will be convertible into common shares of the Company (each, a "Share") at a conversion price of $0.45 per Share, subject to adjustment as provided in the Agreement. If, at any time following four months after the issue date of any Note, the closing price per Share is at least $0.75 per Share for 30 consecutive days with a daily weighted average trading volume of more than 400,000 Shares, the Company may force the conversion of one half of the aggregate principal amount of the outstanding Notes (the "Initial Conversion"). After the first anniversary of the issuance of the Notes, the Company, at its option, may prepay, without notice or penalty, the principal amount of all of the outstanding Notes in full or in part, together with any accrued and unpaid interest. In connection with the issuance of the Initial Notes, the Company issued 400,000 bonus Shares to the purchasers of the Initial Notes. The Company has paid AIP a $100,000 closing fee concurrently with the issuance of the Initial Notes and certain other consideration as provided in the Agreement, a copy of which will be filed on SEDAR. Proceeds from the Notes will be used for the development of the Company's BDaaS technology, for further development of the FlowWorks application, sales and marketing, and for general working capital purposes. Greg Johnston, CEO of Carl, commented, "We're very pleased to have entered into the Agreement and closed the first tranche of the Offering with AIP. It is great to have the confidence of a long-term strategic investor that has expressed an intention to support Carl as we grow. The additional capital will allow Carl to accelerate our business plan by way of acquisitions, the launch of new applications, and expansion of our BDaaS and IoT technology." All securities issued or issuable in connection with the Offering are or will be subject to a statutory hold period expiring on the date that is four months and one day after the distribution date. None of the securities issued or issuable in connection with the Offering will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About AIP Asset Management Inc. AIP Asset Management Inc. ("AIP") is a Toronto based privately held investment firm as - Investment Fund Manager, Portfolio Manager and Exempt Market Dealer. AIP has gained a reputation for its innovative approach to portfolio construction and commitment to investor advocacy. AIP was recently nominated for the Ernst & Young Entrepreneur of the Year Award. AIP has also been named Best Emerging Market Focused Private Investment Firm in North American at the Alternative Investment Awards and was named Best Macro Hedge Fund in Canada at the Hedge Fund Awards sponsored by Barclay Hedge. More information can be found at www.aipassetmanagement.com. About Carl Data Solutions Inc. Carl Data Solutions Inc. is focused on providing next generation information collection, storage and analytics solutions for data centric companies. Building on its recent acquisitions, FlowWorks Inc., a company that helps its clients analyze and understand all forms of environmental data through a powerful platform of data collection, monitoring, analysis, and reporting tools, and Extend to Social Media Inc., a company with an application that allows clients to leverage their customers' social networks for referral marketing and analytics, Carl develops applications to work with new cloud-based mass storage services and analytics applications (Big-Data-as-a-Service (BDaaS)). Carl is creating a virtually unlimited data storage environment from which informative visual representation of data can be created and new insights generated. Carl's goal is to deliver a comprehensive data management solution for datasets of any size and type from any source. More information can be found at www.CarlSolutions.com. On behalf of the Board of Directors: Greg Johnston, President, Chief Executive Officer, Director
Carl Data Solutions Inc. The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release. Disclaimer for Forward-Looking Information Certain statements in this press release related to the Notes and the various loans are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the private placement financing of the Notes, including the proceeds to be raised pursuant to the Note financing, resale restrictions relating to the securities to be issued, and the use of proceeds to be raised pursuant to the Notes and the previously announced equity private placement; a statement that the Note financing will allow the Company to accelerate the development and launch of new applications in data intensive industries; and a statement that Carl's goal is to deliver a comprehensive data management solution for datasets of any size and type from any source. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company's ability to complete the private placement financing for the Notes, including the risk that the entire amount may not be raised as expected or at all, that the proceeds from the Notes may be used other than as set out in this news release and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





Tiffany Tolmie
Corporate Communications
Carl Data Solutions Inc.
(778) 379-0275
[email protected]




Read more...
Carl Data Solutions Awarded Contract Extension for FlowWorks With One of the Fastest Growing Cities in North America

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 10, 2016) - Carl Data Solutions Inc. (CSE:CRL)(FRANKFURT:7C5) ("Carl" or the "Company"), a developer of Big-Data-as-a-Service ("BDaaS")-based solutions for data integration and business intelligence, is pleased to announce that its wholly-owned subsidiary, FlowWorks Inc. ("FlowWorks"), has extended its Services Agreement Contract (the "Contract") with City of Surrey, British Columbia ("Surrey" or the "City") for Carl's FlowWorks Application (the "Application") for another fiscal year. With the inclusion of this contract, FlowWorks now has more than 400 public and private sites that collect a range of environmental sensor data throughout British Columbia, Canada.
Surrey is one of the fastest growing cities in North America and the fastest growing city in Metro Vancouver. The City has taken a lead in adopting progressive environmental plans to responsibly manage its growth. Surrey is recognized as a global leader in sustainability for its waste and pollution reduction, ecosystem and water management, green development and energy conservation initiatives. The City has won multiple awards for its use of technology to achieve its sustainability goals, which include the 2015 Sustainable Communities Award issued by the Federation of Canadian Municipalities for Surrey's Climate Action Strategy Plan, Top 7 finalist for the 2015 Intelligent Community of the Year Award issued by Intelligent Community Forum and the Community Improvement (2011) and Environmental Stewardship (2012) Awards issued by Clean Energy BC. FlowWorks has contributed to the City's environmental efforts since its initial contractual agreement that commenced in 2011. FlowWorks is a powerful Software-as-a-Service ("SaaS")-based application for collecting, monitoring and analyzing environmental data. FlowWorks can collect data from any sensor hardware manufacturer as well as public or private data sources and consolidate the information into one comprehensive analytics and reporting portal made available online at www.FlowWorks.com. Isohyetal Mapping Tool - Surrey is an avid user of FlowWorks' rainfall analysis tools because the City is located within a coastal temperate rainforest zone, which receives an average annual rainfall of 147cm (one of the greatest in North America). Significant rainfall has required Surrey to dedicate a Sediment and Erosion Control Team to work with FlowWorks to develop its own dynamic Isohyetal Mapping Tool. This tool indicates areas of inflated rainfall so the City can manage potential hazards to public infrastructure, local ecosystems and energy networks. The Application aggregates various data sources to create isohyetal maps that show rainfall surface areas and contours, which reveal deep insights into current precipitation patterns throughout the region. ArcGIS Server Geo-Processing Tools - FlowWorks' development team has worked with Surrey to create custom ArcGIS Server geo-processing tools, which provide close to real-time environmental data updates to the various City departments. FlowWorks collects the City's rain gauge data, which is displayed through a customized feature that FlowWorks' team and Surrey partnered to cultivate. The tool allows city planners and developers to make infrastructure development decisions, while taking into account regional weather patterns, which can significantly reduce property damages, energy consumption and overall waste. Inflow & Infiltration Tool - Surrey uses the FlowWorks Inflow & Infiltration ("I&I") Tool to identify points of water infiltration within their wastewater network. This Application feature allows Surrey to take the necessary steps to repair issues within its infrastructure network, which reduces the volume of water that requires treatment at its treatment facilities. Reducing the amount of wastewater requiring treatment contributes significantly to the City's water pollution and energy reduction efforts. Custom Alarms - The City uses the Application to monitor slope stability at specified sites throughout Surrey in order to manage its environmental, ecosystem and public safety processes. Surrey sets custom alarms within the Application, which immediately report slope instabilities and failures to local fire halls and City departments. The City uses the Application's alarming feature for its hydrometric program, which identifies potential rainstorms as well as technical and operational issues at specific stations, reducing the response time of its servicing departments for more proactive environmental management. David Hislop, P.Eng, Drainage Engineer for the City of Surrey, commented, "The FlowWorks team has worked with us to create custom tools that show us near real-time weather information, which allow for the automation of field inspections related to environmental protection and provide easy access to rain event information. FlowWorks provides us the ability to quickly respond to questions from the public and to understand what may be causing the issues that we are experiencing. Surrey has invested significant resources to collect historic rainfall and stream flow data. FlowWorks makes this information available to the general public, academics and engineering designers in an easily accessible and flexible format. It has been a valuable application for us here at the City of Surrey and we look forward to continuing to work with FlowWorks in the future." Greg Johnston, CEO of Carl Data Solutions Inc., commented, "We're pleased that the City of Surrey has chosen FlowWorks to aid in its progressive sustainability plans and manage its environmental data. With the advanced analytics features we'll be adding to the application this year, we're confident that we'll be able to offer the City even better data analytics to drive forward its sustainability efforts. The rapid growth of the City offers FlowWorks the potential to significantly expand its service contract over the coming years, which is very positive for us. Surrey has been a loyal customer for a number of years. We look forward to continuing to offer Surrey the most advanced environmental data monitoring application available." About Carl Data Solutions Inc.
Carl Data Solutions Inc. is focused on providing next generation information collection, storage and analytics solutions for data centric companies. Building on its recent acquisitions, Flow Works Inc., a company that helps its clients analyze and understand all forms of environmental data through a powerful platform of data collection, monitoring, analysis and reporting tools and Extend to Social Media Inc., a company with an application that allows clients to leverage their customers' social networks for referral marketing and analytics, Carl develops applications to work with new cloud-based mass storage services and analytics tools (Big-Data-as-a-Service ("BDaaS")).
Carl is creating a virtually unlimited data storage environment from which informative visual representations of data can be created and new insight generated. Carl's goal is to deliver a comprehensive data management solution for datasets of any size and type from any source. More information can be found at www.CarlSolutions.com. More information on the FlowWorks Application can be found at www.FlowWorks.com.
On behalf of the Board of Directors:
Greg Johnston, President, Chief Executive Officer & Director Carl Data Solutions Inc.
The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking statements in this press release include, but are not limited to, David Hislop's desire to continue to work with FlowWorks in the future, and Greg Johnston's plan to add further predictive analytics features to the FlowWorks Application and the expectation that the City of Surrey will expand its service contract over the coming years.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, risks with respect to: the ability of the Company to establish a market for its services; competitive conditions in the industry; general economic conditions in Canada and globally; the inability to secure additional financing; competition for, among other things, capital and skilled personnel; potential delays or changes in plans with respect to deployment of services or capital expenditures; possibility that government policies or laws may change; technological change; risks related to the Company's competition; the Company's not adequately protecting its intellectual property; interruption or failure of information technology systems; and regulatory risks relating to the Company's business, financings and strategic acquisitions. Any forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.





Carl Data Solutions Inc.
Tiffany Tolmie
Corporate Communications
(778) 379-0275
[email protected]
www.CarlSolutions.com




Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.77
CRL's PE Ratio is ranked higher than
55% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. CRL: 27.77 )
Ranked among companies with meaningful PE Ratio only.
CRL' s PE Ratio Range Over the Past 10 Years
Min: 8.58  Med: 24.64 Max: 95.66
Current: 27.77
8.58
95.66
Forward PE Ratio 17.45
CRL's Forward PE Ratio is ranked higher than
70% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. CRL: 17.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.85
CRL's PE Ratio without NRI is ranked higher than
57% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. CRL: 27.85 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.51  Med: 24.25 Max: 77.86
Current: 27.85
8.51
77.86
Price-to-Owner-Earnings 20.46
CRL's Price-to-Owner-Earnings is ranked higher than
69% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. CRL: 20.46 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.56  Med: 23.14 Max: 323.25
Current: 20.46
10.56
323.25
PB Ratio 5.05
CRL's PB Ratio is ranked lower than
63% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. CRL: 5.05 )
Ranked among companies with meaningful PB Ratio only.
CRL' s PB Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.06 Max: 6
Current: 5.05
0.75
6
PS Ratio 2.57
CRL's PS Ratio is ranked higher than
62% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. CRL: 2.57 )
Ranked among companies with meaningful PS Ratio only.
CRL' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 2.22 Max: 3.82
Current: 2.57
1.11
3.82
Price-to-Free-Cash-Flow 17.52
CRL's Price-to-Free-Cash-Flow is ranked higher than
68% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. CRL: 17.52 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.62  Med: 16.71 Max: 765.42
Current: 17.52
8.62
765.42
Price-to-Operating-Cash-Flow 14.30
CRL's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. CRL: 14.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79  Med: 12.41 Max: 20.15
Current: 14.3
4.79
20.15
EV-to-EBIT 21.68
CRL's EV-to-EBIT is ranked higher than
52% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. CRL: 21.68 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.8 Max: 27.8
Current: 21.68
-10.7
27.8
EV-to-EBITDA 14.43
CRL's EV-to-EBITDA is ranked higher than
65% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. CRL: 14.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 12.1 Max: 16.8
Current: 14.43
-16.5
16.8
PEG Ratio 3.03
CRL's PEG Ratio is ranked lower than
51% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. CRL: 3.03 )
Ranked among companies with meaningful PEG Ratio only.
CRL' s PEG Ratio Range Over the Past 10 Years
Min: 1.08  Med: 2.64 Max: 3.28
Current: 3.03
1.08
3.28
Shiller PE Ratio 168.73
CRL's Shiller PE Ratio is ranked lower than
100% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. CRL: 168.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 90.11  Med: 162.56 Max: 1552.4
Current: 168.73
90.11
1552.4
Current Ratio 1.53
CRL's Current Ratio is ranked lower than
75% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. CRL: 1.53 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 1.96 Max: 3.24
Current: 1.53
1.35
3.24
Quick Ratio 1.31
CRL's Quick Ratio is ranked lower than
73% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. CRL: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.65 Max: 2.79
Current: 1.31
0.97
2.79
Days Inventory 34.16
CRL's Days Inventory is ranked higher than
67% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. CRL: 34.16 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 33.43  Med: 41.32 Max: 49.49
Current: 34.16
33.43
49.49
Days Sales Outstanding 61.18
CRL's Days Sales Outstanding is ranked higher than
52% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. CRL: 61.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.61 Max: 65.6
Current: 61.18
53.42
65.6
Days Payable 24.16
CRL's Days Payable is ranked lower than
80% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. CRL: 24.16 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.77 Max: 24.16
Current: 24.16
14.93
24.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
CRL's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. CRL: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.6  Med: 0.3 Max: 10.3
Current: 0.1
-62.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.37
CRL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. CRL: 1.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.33 Max: 1.76
Current: 1.37
0.95
1.76
Price-to-Median-PS-Value 1.15
CRL's Price-to-Median-PS-Value is ranked lower than
58% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CRL: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.14 Max: 1.65
Current: 1.15
0.56
1.65
Price-to-Peter-Lynch-Fair-Value 3.16
CRL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
70% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. CRL: 3.16 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.13  Med: 2.68 Max: 3.17
Current: 3.16
1.13
3.17
Earnings Yield (Greenblatt) % 4.60
CRL's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. CRL: 4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.6  Med: 5.4 Max: 14.1
Current: 4.6
3.6
14.1
Forward Rate of Return (Yacktman) % 13.46
CRL's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. CRL: 13.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.8  Med: 5.6 Max: 21.3
Current: 13.46
2.8
21.3

More Statistics

Revenue (TTM) (Mil) $1,681
EPS (TTM) $ 3.23
Beta0.96
Short Percentage of Float5.34%
52-Week Range $67.20 - 91.57
Shares Outstanding (Mil)47.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,836 1,968 2,107
EPS ($) 5.08 5.62 5.91
EPS without NRI ($) 5.08 5.62 5.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.52%
Dividends per Share ($)
» More Articles for CRL

Headlines

Articles On GuruFocus.com
5 Best Stocks for Value Investors This Week - Feb. 25 Feb 26 2017 
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017 
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017 
Bob Olstein's Olstein Strategic Opportunities Fund 2nd Quarter Commentary Sep 01 2016 
Carl Data Solutions Announces Closing of Initial Tranche of $2,000,000 Growth Financing Agreement Wi Jun 30 2016 
Olstein Strategic Opportunities Fund 1st Quarter Letter to Shareholders Jun 07 2016 
Olstein All Cap Value Fund First Quarter Commentary Jun 01 2016 
Carl Data Solutions Awarded Contract Extension for FlowWorks With One of the Fastest Growing Cities May 10 2016 
Carl Announces Commitment Letter for $2M Convertible Debenture Financing and Issuance of Commitment Apr 25 2016 
Carl Awarded Contract Extension With City of Kimberley for Its FlowWorks Application Apr 12 2016 

More From Other Websites
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish... Apr 26 2017
Charles River Laboratories Schedules First-Quarter 2017 Earnings Release and Conference Call Apr 12 2017
Charles River Laboratories International, Inc. – Value Analysis (NYSE:CRL) : April 12, 2017 Apr 12 2017
Parexel Is Discovering the Drugs of the Future Apr 10 2017
Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New... Apr 05 2017
Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology... Apr 03 2017
Charles River Labs settles with feds over NIH billing flap Mar 14 2017
Company to pay $1.8M to settle claims of overbilling Mar 13 2017
Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory... Mar 13 2017
Charles River Laboratories to Present at Raymond James and Barclays Conferences Mar 06 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers :... Feb 16 2017
Edited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT Feb 14 2017
Charles River tops Street 4Q forecasts Feb 14 2017
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing... Feb 14 2017
Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q Feb 13 2017
Charles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference... Feb 09 2017
Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics Jan 30 2017
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)